I-1 (Life Sciences Law) (Release 2006) INDEX [References are to chapter- and heading-numbers, with initial abbreviations and ac- ronyms appearing before full-text words.] AHR – see Assisted Human Reproduction AHRAC – see Assisted Human Reproduc- tion Agency of Canada ANDS – see Abbreviated New Drug Sub- missions APS – see Advertising/Promotion Systems ASC – see Advertising Standards Canada Abbreviated New Drug Submissions data protection and, 9.1, 9.4 drug identification number and, 1.3(1) notice of compliance and, 1.3(2), 4.3 supplemental, 1.6 Act to Amend the Patent Act and the Food and Drugs Act Bill C-56, 8.4 Adverse Drug Reaction post-market surveillance and, 1.5 Advertising – see Marketing Advertising/Promotion Systems marketing to health care professionals, 12.5(1) Advertising Standards Canada consumer advertising, 12.4(2) regulatory control over marketing, 12.3 Agreement on Trade-Related Aspects of In- tellectual Property Rights Canadian previous obligations • Berne Convention for the Protection of Liter- ary and Artistic Works, 7.2(1) • Canada-U.S. Free Trade Agreement, 7.2(3) • General Agreement on Tariffs and Trade, 7.2(2) • Paris Convention for the Protection of Indus- trial Property, 7.2(1) cross-border pharmaceutical trade rules and, 10.2 data protection and, 9.2 Declaration on the TRIPS Agreement and Pub- lic Health, 8.2 dispute settlement mechanisms • pharmaceutical patents, 7.6(1)(b) • term of patent protection, 7.6(1)(a) Doha Declaration of 2001 and, 8.2 implementation in Canada • Bill C-22, 7.4(1) • Bill C-91, 7.4(2) • generally, 7.4 • legislation, 7.4(3) international obligations and, 7.1 life sciences products, relevant provisions re • basic obligations, 7.5(1) • data protection, 7.5(7) • enforcement, 7.5(8) • exceptions, limited, 7.5(5) • licensing, compulsory, 7.5(6) • non-discrimination, 7.5(2) • patent protection, term of, 7.5(4) • patent rights, 7.5(3) • patentability, 7.5(2) negotiations, 7.3(1) Assisted Human Reproduction Act generally, 16.2.1, 16.2.4 framework of Act • Assisted Human Reproduction Agency of Canada, 16.2.3(4) • generally, 16.2.3 • goals, 16.2.3(1) • offences, 16.2.3(5)
22
Embed
INDEX [products.thomsonreuters.ca] · CTA see Clinical Trial Application CTA-As see Clinical Trial Application Amendments Canada-United States Free Trade Agreement Canadian obligationsprior
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
I-1 (Life Sciences Law) (Release 2006)
INDEX
[References are to chapter- and heading-numbers, with initial abbreviations and ac-ronyms appearing before full-text words.]
AHR – see Assisted Human Reproduction
AHRAC – see Assisted Human Reproduc-tion Agency of Canada
ANDS – see Abbreviated New Drug Sub-missions
APS – see Advertising/Promotion Systems
ASC – see Advertising Standards Canada
Abbreviated New Drug Submissionsdata protection and, 9.1, 9.4drug identification number and, 1.3(1)notice of compliance and, 1.3(2), 4.3supplemental, 1.6
Act to Amend the Patent Act and the Foodand Drugs Act
Bill C-56, 8.4
Adverse Drug Reactionpost-market surveillance and, 1.5
Advertising – see Marketing
Advertising/Promotion Systemsmarketing to health care professionals,
12.5(1)
Advertising Standards Canadaconsumer advertising, 12.4(2)regulatory control over marketing, 12.3
Agreement on Trade-Related Aspects of In-tellectual Property Rights
Canadian previous obligations• Berne Convention for the Protection of Liter-
ary and Artistic Works, 7.2(1)
• Canada-U.S. Free Trade Agreement, 7.2(3)• General Agreement on Tariffs and Trade,
7.2(2)• Paris Convention for the Protection of Indus-
Copyright Act – see Copyright, or Chapter 6generally
implementation of TRIPS and NAFTA,7.4(3)
Cosmetic Regulationsadvertising, labelling and marketing, 12.2
Criminal Codeadvertising, labelling and marketing, 12.2(3)
Cross-Border Pharmaceutical TradeCanadian Internet pharmacy industry• generally, 10.1• mechanics of trade, 10.1(3)• rationale for, 10.1(4)• scope of trade, 10.1(2)international trade rules governing, 10.2regulatory laws, applicable• Canadian drug laws, 10.3(2)• generally, 10.3• proposed legislation, 10.3(4)• provincial regulatory standards, 10.3(3)• United States drug laws, 10.3(1)
DIN – see Drug Identification Number
DSU – see Dispute Settlement Understand-ing
DTC – see direct to customer advertising(under Marketing)
Data ProtectionCanada, in, 9.4Canadian international obligations, 9.2countries, in other, 9.3generally, 9.1proposed regulations for, 9.5Regulatory Impact Analysis Statement, 9.5
Declaration on the TRIPS Agreement andPublic Health
compulsory licensing of patents and, 8.2
� LIFE SCIENCES LAW IN CANADA
I-4
Dispute Settlement Understandingmechanisms under TRIPS and NAFTA, 7.6
DohaDecision of August 30, 2003• exporting obligations, 8.3(2)• General Council Chairperson’s Statement,
8.3(4)• generally, 8.3• importing obligations, 8.3(2)• WTO members, obligations on, 8.3(3)Declaration of 2001, 8.2Declaration on the TRIPS Agreement and Pub-
data protection and, 9.2dispute settlement mechanisms• generally, 7.6
[Next page is I-7.]
INDEX �
I-7 (Life Sciences Law) (Release 2006)
• NAFTA, 7.6(2)• pharmaceutical patents, 7.6(1)(b)• TRIPS, 7.6(1)• term of patent protection, 7.6(1)(a)generally, 7.1, 7.7implementation in Canada• Bill C-22, 7.4(1)• Bill C-91, 7.4(2)• generally, 7.4• legislation, 7.4(3)licensing, compulsory• Act to Amend the Patent Act and the Food
and Drugs Act, 8.4• anti-diversion measures, 8.4(2)• Bill C-9, 8.4• Bill C-56, 8.4• Doha Decision, 8.3• Doha Declaration, 8.2• duration, 8.4(4)• framework, 8.4(1)• Jean Chretien Pledge to Africa (JCPA), 8.4• royalty, 8.4(3)• termination, 8.4(5)life sciences products, relevant provisions re• basic obligations, 7.5(1)• data protection, 7.5(7)• enforcement, 7.5(8)• exceptions, limited, 7.5(5)• licensing, compulsory, 7.5(6)• non-discrimination, 7.5(2)• patent protection, term of, 7.5(4)• patent rights, 7.5(3)• patentability, 7.5(2)negotiations• NAFTA, 7.3(2)• TRIPS, 7.3(1)
JCPA – see Jean Chretien Pledge to Africa
Jean Chretien Pledge to AfricaBill C-9, 8.1, 8.4
LA/SA – see Look Alike Sound Alike
LOI – see Letter of Intent
Labelling – see Marketing
Letter of Intentoutsourcing and, 16.4.3(2)
Licencescompulsory – see also Chapter 8 generally• anti-diversion measures, 8.4(2)• Canadian legislation, 8.4• commercial nature, agreements of, 8.5• Doha Decision, 8.3• Doha Declaration of 2001, 8.2• duration, 8.4(4)• exporting obligations, 8.3(2)• framework, 8.4(1)• General Council Chairperson’s Statement,
8.3(4)• generally, 8.1• importing obligations, 8.3(2)• royalty, 8.4(3)• termination, 8.4(5)establishment• drugs, 1.3(3)(a)• medical devices, 1.9(2)product• amending, 1.11(3)(b)• application for, 1.11(3)(a)• cancellation of, 1.11(3)(c)• generally, 1.11(3)• reporting obligations, 1.11(3)(d)• suspension of, 1.11(3)(c)site, 1.11(4)technology transfer – see Technology Trans-
fer
Licensing Services Divisionsubmissions and review, 1.7(1)
Linkage Regulations – see Patented Medi-cines
Look Alike Sound Aliketrademarks, 5.1(7)
MOU – see Memorandum of Understanding
MTAs – see Material Transfer Agreements
� LIFE SCIENCES LAW IN CANADA
I-8
Manufacturingapplication of good practices, 1.3(3)(b)establishment licences, 1.3(3)(a)establishments and, 1.3(3)good practices, 1.3(3)natural health products, 1.3(3)(a)standards for, 1.3(3)
Marketed Health Products Directoratemarketing, advertising and labelling, 12.3(1)
Marketingadvertising – see labelling and advertisingapproval• abbreviated new drug submission, 1.3(1),
1.3(2)• compliance, notice of, 1.3(2)• drug identification number, 1.3(1)• drug submissions, 1.3(1), 1.3(2)• generally, 1.3• good manufacturing practices, 1.3(3)• new drug submission, 1.3(1), 1.3(2)• notice of compliance, 1.3(2)• standards – see standards for approvaldirect to customer advertising, 12.4(1)health care professionals• generally, 12.5• Pharmaceutical Advertising Advisory
Board, 12.5(1)• provincial medical associations, 12.5(3)• research-based pharmaceutical companies,
12.5(2)labelling and advertising• Advertising Standards Canada, 12.3(2)• consumer advertising, 12.4• deceptive advertising, 12.2(3)• definitions, 12.2(1)• false advertising, 12.2(3)• framework, 12.2• future directions, 12.6• generally, 12.1• health care professionals – see health care
professionals• Health Canada, 12.3(1)• legislative provisions, 12.2(2)• medical devices, 12.4(3)• misleading advertising, 12.2(3)
Minister of Industrypricing of medicines and, 11.1(1)
NAFTA – see North American Free TradeAgreement
NDAs – see Non-Disclosure Agreements
NDS – see New Drug Submissions
NHP – see Natural Health Product
NHPD – see Natural Health Product Direc-torate
NOA – see Notice of Allegation
NOC – see Notice of Compliance
NOC/c – see Notice of Compliance withConditions
NOD – see Notice of Deficiency
NON – see Notice of Non-Compliance
NRPI – see National Pollutant Release In-ventory
National Pollutant Release InventoryCanadian Environmental Protection Act, 1999,
and, 15.2(1)(d)
Natural Health Productadvertising – see Marketingclinical trials on humans, 1.11(6)• authorization, 1.11(6)(a), 1.11(6)(b)• cancellation of authorization, 1.11(6)(b)• sponsor obligations and, 1.11(6)(c)• suspension of authorization, 1.11(6)(b)compliance, 1.11(8)
� LIFE SCIENCES LAW IN CANADA
I-10
defined, 12.2(1)directorate, 1.11(3)(a), 12.3(1)enforcement, 1.11(8)establishments, standards for, 1.3(3)generally, 1.11good manufacturing practices re, 1.11(5)labelling, 1.11(7) – see also Marketingmanufacturing, standards, for, 1.3(3)packaging, 1.11(7)product licences• amending, 1.11(3)(b)• application for, 1.11(3)(a)• cancellation of, 1.11(3)(c)• generally, 1.11(3)• reporting obligations, 1.11(3)(d)• suspension of, 1.11(3)(c)regulations re• advertising, 12.2, 12.4(2)• generally, 1.11• history, 1.11(1)• labelling, 12.2• marketing, 12.2• scope, 1.11(2)site licences, 1.11(4)transition, 1.11(8)
Natural Health Product Directorate – seealso Natural Health Product
generally, 1.11(3)(a)marketing, advertising and labelling, 12.3(1)
New Drug Submissionsabbreviated – see Abbreviated New Drug
Submissionsdrug identification number and, 1.3(1)notice of compliance and, 1.3(2), 4.3patent listing and, 4.5(4)supplemental, 1.6, 4.5(4)
Non-Disclosure Agreementstechnology transfer and, 13.2(1)
North American Free Trade AgreementCanadian previous obligations• Berne Convention for the Protection of Liter-
ary and Artistic Works, 7.2(1)• Canada-U.S. Free Trade Agreement, 7.2(3)
• General Agreement on Tariffs and Trade,7.2(2)
• Paris Convention for the Protection of Indus-trial Property, 7.2(1)
data protection and, 9.2dispute settlement, 7.6(2)implementation in Canada• Bill C-22, 7.4(1)• Bill C-91, 7.4(2)• generally, 7.4• legislation, 7.4(3)international obligations and, 7.1life sciences products, relevant provisions re• basic obligations, 7.5(1)• data protection, 7.5(7)• enforcement, 7.5(8)• exceptions, limited, 7.5(5)• licensing, compulsory, 7.5(6)• non-discrimination, 7.5(2)• patent protection, term of, 7.5(4)• patent rights, 7.5(3)• patentability, 7.5(2)negotiations, 7.3(2)
North American Free Trade Agreement Im-plementation Act
Canadian implementation of, 7.4
Notice of AllegationNOC Regulations and• challenges to, 4.6(3)• generally, 4.3, 4.6(1)• sufficiency of, 4.6(2)
Notice of Allowancepatent, of, 2.2(12)
Notice of Compliancechanges to new drugs and, 1.6conditions, with, 1.7(1)data protection, 9.4marketing approval and, 1.3(2)NOC-regulation – see Patented Medicinesregulation re – see Patented Medicinessubmissions and review, 1.7(1)
INDEX �
I-11 (Life Sciences Law) (Release 2007-2)
Notice of Compliance with Conditionssubmissions and review, 1.7(1)
Notice of Deficiencysubmissions and review, 1.7(2)(a)(iv)withdrawal letter, 1.7(2)(a)(iv)
Notice of Non-Compliancesubmissions and review, 1.7(2)(a)(v)withdrawal letter, 1.7(2)(a)(v)
Patent Act – see also Patents, or Chapters 2,3 and 4 generally
Bill C-9, 8.4Bill C-22, 11.1(1)Bill C-56, 8.4Bill C-91, 11.1(1)compulsory licensing and, 8.4, 8.5dispute settlement cases under TRIPS, 7.6(1)implementation of TRIPS and NAFTA, 7.4international obligations and, 7.1pricing and, 11.1(1)regulations, 8.4(2), 8.4(3) – see also Patented
Medicines
Patent Act Amendment Act, 1992 – see alsoPatented Medicines
Bill C-91 and, 7.4(2)patented medicines and, 4.1
Patent Appeal Boardprosecution of application, 2.2(11)
Patent Cooperation Treatypatentability of DNA, RNA and antibodies,
2.6(3)(a)patentability of life forms, 2.5(3)prosecution of application and, 2.2(4)
Patent Registerpatent listing and, 4.5
Patent Rules – see Patents
Patented Medicinesappeal from Federal Court (Trial Level), 4.8Bill C-22 and, 7.4(1)Bill C-91 and, 7.4(2)damages, legislative, 4.9generally, 4.1, 4.10
� LIFE SCIENCES LAW IN CANADA
I-12
international obligations and, 7.4, 7.7Notice of Allegation• challenges to, 4.6(3)• generally, 4.6(1)• sufficiency of, 4.6(2)patent listing• eligibility for, 4.5(2)• entitlement to list, who has, 4.5(1)• generally, 4.5• invalidity, allegations re, 4.6(4)• non-infringement, allegations re, 4.6(5)• Notice of Allegation – see Notice of Alle-
gation• prior to June 17, 2006, 4-Appendix A• submission, nature of associated, 4.5(4)• timing requirements, 4.5(3)Prices Review Board – see Patented Medi-
cines Prices Review Board, or Chapter 11generally
proceedings re• burden of proof, 4.7(2)• generally, 4.4• indirect infringement, 4.7(3)• infringement action distinguished, 4.4• initiating, 4.7• time period for, 4.7(1)regulations• appeal from Federal Court (Trial Level),
4.8• damages, 4.9• framework of, 4.3• generally, 4.1• policy concerns, 4.2• proceedings, 4.4 – see also proceedings re
Patented Medicines (Notice of Compliance)Regulations – see Patented Medicines orChapter 4 generally
guished, 4.4• preliminary motions, 3.3(2)(b)(ii)• pre-litigation, 3.3(1)• Provincial Superior Court, 3.3(2)(a)(ii)• procedural steps, 3.3(2)(b)• relief to be sought, 3.5(3)• Reply and Defence to Counterclaim,
3.3(2)(b)(i)• Reply to Defence to Counterclaim,
3.3(2)(b)(i)• Statement of Claim, 3.3(2)(b)(i)• Statement of Defence and Counterclaim,
3.3(2)(b)(i)• trial, 3.3(2)(b)(v)law re – see Chapters 2, 3, 4 generallylegislation – see Chapters 2, 3, 4 generallylife forms, patentability of• Abitibi case, 2.5(1)• biological matters, deposit of, 2.5(3)• Harvard Mouse case, 2.5(4)• Monsanto case, 2.5(5)• Pioneer Hi-Bred case, 2.5(2)listing, 4.5 – see also Patented Medicinesmedical treatment claims, 2.4(2) – see also
chemical and pharmaceutical claimsmedicines – see Patented MedicinesParis Convention for the Protection of Industrial
Property, 2.2(1)Patent Cooperation Treaty, 2.2(4)patentability• antibodies – see genetics• anticipation, 2.3(1)• DNA – see genetics• double-patenting, 2.3(2)• eggs fertilized, 2.6(5)(2)• inventiveness, 2.3(1)• life forms, 2.5 – see also life forms, patenta-
bility of• novelty, 2.3(1)
INDEX �
I-14.1 (Life Sciences Law) (Release 2010 – 1)
• obviousness, test for, 2.3(1)• Organs, 2.6(5)(3)• overlapping subject matter, 2.3(2)• RNA – see genetics• requirements, 2.3• specification, sufficiency of, 2.3(3)• stem cells, 2.6(5)(1)• subject application, 2.3(1)• tissues, 2.6(5)(3)
[Next page is I-15.]
INDEX �
I-15 (Life Sciences Law) (Release 2006)
• utility, 2.3(4)pharmaceutical claims, 2.4 – see also chemi-
cal and pharmaceutical claimproceedings, 3.3 – see also infringement pro-
ceedingsprosecution – see application, prosecution of
Personal Information Protection and Elec-tronic Documents Act
legislative overview and, 16.1.2personal health information and, 16.1.4
Pharmaceutical Advertising AdvisoryBoard
marketing, advertising and labelling, 12.3(1),12.5(1)
Plant Breeders’ Rights Actpatentability of life forms, 2.5(5)
Policies – see Index to Guidelines, Policies,Papers and Other Non-Legislative Materi-als
Post-Market Surveillanceregulation of products and, 1.5
Pricing – see Patented Medicine Prices Re-view Board
Privacy Lawcompliance, implementing, 16.1.6federal Privacy Act, 16.1.2generally, 16.1genetic information, 16.1.5health information, 16.1.4legislative overview, 16.1.2Model Code for the Protection of Personal Infor-
mation, 16.1.3Ontario’s Personal Health Information Protec-
tion Act, 16.1.2, 16.1.4, 16.1.5personal genetic information, 16.1.5personal health information, 16.1.4Personal Information Protection and Electronic
Product Specific Facility Informationgenerally, 1.4
RFI – see Request for Information
RFP – see Request for Proposals
RFQ – see Request for Quotes
Radiopharmaceuticalsregulation of products and, 1.4
Regulation of Productschanges to drugs after approval, 1.6clinical trials, 1.8combination products, 1.10
� LIFE SCIENCES LAW IN CANADA
I-16
Controlled Drugs and Substances Act, 1.1drugs – see DrugsFood and Drugs Act, 1generally, 1Health Products and Food Branch, 1.1marketing approval, 1.3 – see also Marketing
Approvalmedical devices, 1.9 – see also Medical De-
vicesMinister of Health, 1.1natural health products – see also Natural
Health Product• generally, 1.11• standards re, 1.3(3)(a)post-market surveillance, 1.5review process – see also Submissionssale of products, 1.2, 1.9submissions, 1.7 – see also Submissionssurveillance, post-market, 1.5
Request for Informationoutsourcing and, 16.4.2
Request for Proposalsoutsourcing and, 16.4.2
Request for Quotesoutsourcing and, 16.4.2
Research-Based Pharmaceutical Com-panies
health care professionals, marketing to,12.5(2)
regulatory control over marketing, 12.3(4)
Review Process – see also Submissionsgenerally, 1.7priority, 1.7(1)
SANDS – see Supplemental AbbreviatedNew Drug Submissions
SNDS – see Supplemental New Drug Sub-missions
Sale of ProductsCanada, in, 1.2, 1.9regulation of products and, 1.2, 1.9
Screening Deficiency Noticesubmissions and review, 1.7(2)(a)(i)
Serious Adverse Drug Reactionpost-market surveillance and, 1.5
Site Licencesnatural health products and, 1.11(4)
Special Accessmedical devices and, 1.9(3)
Standardsestablishment licences, 1.3(3)(a)establishments, for, 1.3(3)good manufacturing practices• application of, 1.3(3)(b)• generally, 1.3(3)licences, establishment, 1.3(3)(a)manufacturing, for, 1.3(3)natural health products, 1.3(3)(a)
Submissions – see also Abbreviated NewDrug Submissions; New Drug Submis-sions
generally, 1.7information permitted, 1.7(2) – see also solic-
Supplemental New Drug Submissionschanges to new drugs once approved, 1.6patent listing and, 4.5(4)
Surveillancepost-market, 1.5
TMA – see terms of market authorization(under Marketing)
TPCC – see Therapeutic Products Classifi-cation Committee
TPD – see Therapeutic Products Director-ate
TRIPS – see Agreement on Trade-Related As-pects of Intellectual Property Rights
Tax Issuesgenerally, 16.3goods and services tax, 16.3.5scientific research and experimental develop-
ment, 16.3.2tax credits, 16.3.2transfer pricing rules, 16.3.3withholding tax, 16.3.4
Technology Transferagreements, common types of• co-promotion agreements, 13.2(6)• development agreements, 13.2(3)• distribution agreements, 13.2(5)• generally, 13.2• licensing agreements, 13.2(4)
• material transfer agreements, 13.2(2)• non-disclosure agreements, 13.2(1)confidential information defined, 13.2(1)contractual terms, common• alternative dispute resolution, 13.3(13)(b)• assignment of control, 13.3(13)(h)• boilerplate, 13.3(13)• change of control, 13.3(13)(h)• choice of law, 13.3(13)(a)• compliance with laws, 13.3(13)(e)• confidentiality, 13.3(8)• definitions, 13.3(1)• definitions, improvements re, 13.3(7)(a)• disclaimers, 13.3(10)• entirety of contract, 13.3(13)(c)• force majeure, 13.3(13)(f)• form of payment, 13.3(6)(d)• further assurance, 13.3(13)(g)• generally, 13.3• grant clause, 13.3(3)• grant, improvements re, 13.3(7)(c)• implied terms, 13.3(5)• improvements, 13.3(7)• indemnities, 13.3(11)• independence of parties, 13.3(13)(k)• infringement, indemnities from,
13.3(11)(a)• licence estoppel, 13.3(4)• licence, nature of, 13.3(2)• lump sum payments, 13.3(6)(a)• minimum payments, 13.3(6)(c)• non-waiver, 13.3(13)(j)• notices, 13.3(13)(l)• payment terms, 13.3(6)• records and audits, 13.3(6)(e)• remedies on termination, 13.3(12)(e)• renewal rights, 13.3(12)(b)• reporting, improvements re, 13.3(7)(b)• representations, 13.3(9)• royalties, 13.3(6)(b)• severability, 13.3(13)(d)• surviving provisions, 13.3(13)(i)• term, 13.3(1)• termination, 13.3(12)• termination, consequences of, 13.3(12)(d)• termination, grounds for, 13.3(12)(c)
World Trade Organization Agreement Im-plementation Act
TRIPS, Canadian implementation of, 7.4
� LIFE SCIENCES LAW IN CANADA
I-20
Index to Guidelines, Policies, Papers and Other Non-LegislativeMaterials
CIRA Policies, Rules and Procedures – General Regulation Rules, 5.2(1)CIRA’s Dispute Resolution Policy, 5.2(2)Changes in Manufacturer’s Name and/or Product Name, 1.7(2)(b)(v)Changes to Marketed New Drugs, 1.6Code of Advertising Acceptance, 12.3(3), 12.3(4)Compendium of Guidelines, Policies and Procedures, 11.1(3)(c)Compliance with Paragraph 30(a) of the Trade-marks Act – Pharmaceuticals, 5.1(2)(a)Compliance Policy, 11.1(3)(b)Compliance Policy for Natural Health Products, 1.11(8)Consumer Advertising Guidelines for Marketed Health Products (draft), 12.3(2)Consumer Drug Advertising Guideline, 12.3(2), 12.4(2)Drug Name Review: Look-Alike Sound-Alike (LA/SA) Health Product Names, 5.1(7)Good Clinical Practice Consolidated Guideline, 1.8Guidelines for General Advertising, Supplied Advertising Inserts & Journal Supplements, 12.3(4),
12.5(2)Management of Drug Submission Policy, 1.10Manual of Patent Office Practice, 2.5(5)Marketed Health Product Name Assessment: Look-alike Sound-alike (LA/SA) Health Product Names,
5.1(7)Natural Health Products: A New Vision, 1.11(1)Principles for Claims Relating to Comparison of Non-Therapeutic Aspects of Non-Prescription Drug
Products, 12.4(2)Regulatory Framework for Natural Health Products, 1.11(1)Report on Prescription Drug Importation, 10.1(2)Therapeutic Comparative Advertising: Directive and Guidance Document, 12.4(2)Trade-marks Journal, 5.1(2)(b)Trade-marks Wares and Services Manual, 5.1(2)(a)Tri-Council Policy Statement on Ethical Conduct for Research Involving Humans, 1.8Uniform Dispute Resolution Policy, 5.2(2)Working Group recommendations, 12.2(2)